Benitec Biopharma Ltd Net Income
| BNTC Stock | USD 11.65 0.76 6.12% |
As of the 5th of February, Benitec Biopharma shows the Standard Deviation of 4.76, mean deviation of 3.22, and Risk Adjusted Performance of (0.05). Benitec Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Benitec Biopharma Total Revenue |
|
Market Capitalization | Enterprise Value Revenue 10.5 K | Revenue | Earnings Share (1.07) | Quarterly Revenue Growth 0.125 |
| Last Reported | Projected for Next Year | ||
| Net Loss | -34.1 M | -32.4 M | |
| Net Loss | -34.1 M | -32.4 M | |
| Net Loss | -17.6 M | -18.5 M | |
| Net Loss | (0.94) | (0.99) | |
| Net Income Per E B T | 0.85 | 0.75 |
Benitec | Net Income | Build AI portfolio with Benitec Stock |
Analyzing Benitec Biopharma's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Benitec Biopharma's current valuation and future prospects.
Latest Benitec Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of Benitec Biopharma Ltd over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Benitec Biopharma financial statement analysis. It represents the amount of money remaining after all of Benitec Biopharma Ltd operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Benitec Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Benitec Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (37.92 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Benitec Net Income Regression Statistics
| Arithmetic Mean | (14,919,558) | |
| Geometric Mean | 11,882,672 | |
| Coefficient Of Variation | (76.41) | |
| Mean Deviation | 9,182,256 | |
| Median | (10,835,671) | |
| Standard Deviation | 11,400,642 | |
| Sample Variance | 130T | |
| Range | 40.8M | |
| R-Value | (0.77) | |
| Mean Square Error | 57.1T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (1,730,887) | |
| Total Sum of Squares | 2079.6T |
Benitec Net Income History
Other Fundumenentals of Benitec Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Benitec Biopharma Net Income component correlations
Benitec Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Benitec Biopharma is extremely important. It helps to project a fair market value of Benitec Stock properly, considering its historical fundamentals such as Net Income. Since Benitec Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Benitec Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Benitec Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Benitec diversify its offerings? Factors like these will boost the valuation of Benitec Biopharma. Projected growth potential of Benitec fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Benitec Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.07) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Benitec Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Benitec Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Benitec Biopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Benitec Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Benitec Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Benitec Biopharma.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Benitec Biopharma on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Benitec Biopharma Ltd or generate 0.0% return on investment in Benitec Biopharma over 90 days. Benitec Biopharma is related to or competes with Solid Biosciences, Neurogene, Autolus Therapeutics, QuantumSi, PureTech Health, Lineage Cell, and XOMA Corp. Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines More
Benitec Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Benitec Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Benitec Biopharma Ltd upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 24.4 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 5.86 |
Benitec Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Benitec Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Benitec Biopharma's standard deviation. In reality, there are many statistical measures that can use Benitec Biopharma historical prices to predict the future Benitec Biopharma's volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (0.62) | |||
| Treynor Ratio | (0.27) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Benitec Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Benitec Biopharma February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.22 | |||
| Coefficient Of Variation | (1,214) | |||
| Standard Deviation | 4.76 | |||
| Variance | 22.67 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (0.62) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 24.4 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 5.86 | |||
| Skewness | (2.04) | |||
| Kurtosis | 8.63 |
Benitec Biopharma Backtested Returns
Benitec Biopharma secures Sharpe Ratio (or Efficiency) of -0.0216, which signifies that the company had a -0.0216 % return per unit of risk over the last 3 months. Benitec Biopharma Ltd exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Benitec Biopharma's Risk Adjusted Performance of (0.05), mean deviation of 3.22, and Standard Deviation of 4.76 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.47, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Benitec Biopharma will likely underperform. At this point, Benitec Biopharma has a negative expected return of -0.0815%. Please make sure to confirm Benitec Biopharma's maximum drawdown, as well as the relationship between the accumulation distribution and day typical price , to decide if Benitec Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.26 |
Poor predictability
Benitec Biopharma Ltd has poor predictability. Overlapping area represents the amount of predictability between Benitec Biopharma time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Benitec Biopharma price movement. The serial correlation of 0.26 indicates that nearly 26.0% of current Benitec Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.26 | |
| Spearman Rank Test | 0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.31 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Benitec Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Benitec Biopharma Ltd reported net income of (37.92 Million). This is 111.11% lower than that of the Biotechnology sector and 154.13% lower than that of the Health Care industry. The net income for all United States stocks is 106.64% higher than that of the company.
Benitec Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Benitec Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Benitec Biopharma could also be used in its relative valuation, which is a method of valuing Benitec Biopharma by comparing valuation metrics of similar companies.Benitec Biopharma is currently under evaluation in net income category among its peers.
Benitec Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Benitec Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Benitec Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Benitec Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Benitec Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Benitec Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Benitec Biopharma's value.| Shares | Awm Investment Company Inc | 2025-06-30 | 138 K | Northern Trust Corp | 2025-06-30 | 126.3 K | Ameriprise Financial Inc | 2025-06-30 | 109.9 K | Exoduspoint Capital Management, Lp | 2025-06-30 | 76.4 K | Simplify Asset Management Inc. | 2025-06-30 | 69.2 K | Myda Advisors Llc | 2025-06-30 | 62.1 K | Lion Point Capital, Lp | 2025-06-30 | 62 K | Longaeva Partners L.p. | 2025-06-30 | 52 K | Charles Schwab Investment Management Inc | 2025-06-30 | 45.3 K | Suvretta Capital Management, Llc | 2025-06-30 | 9.9 M | Hhg Plc | 2025-06-30 | 2.9 M |
Benitec Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 333.15 M | ||||
| Shares Outstanding | 34.25 M | ||||
| Shares Owned By Insiders | 2.74 % | ||||
| Shares Owned By Institutions | 82.48 % | ||||
| Number Of Shares Shorted | 1.94 M | ||||
| Price To Earning | (5.10) X | ||||
| Price To Book | 4.62 X | ||||
| Price To Sales | 2,770 X | ||||
| EBITDA | (41.7 M) | ||||
| Net Income | (37.92 M) | ||||
| Cash And Equivalents | 4.06 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 849 K | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 3.57 X | ||||
| Cash Flow From Operations | (23.59 M) | ||||
| Short Ratio | 9.90 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 23.83 | ||||
| Number Of Employees | 19 | ||||
| Beta | 0.29 | ||||
| Market Capitalization | 425.1 M | ||||
| Total Asset | 99.59 M | ||||
| Retained Earnings | (228.18 M) | ||||
| Working Capital | 96.72 M | ||||
| Current Asset | 19.38 M | ||||
| Current Liabilities | 1.03 M | ||||
| Net Asset | 99.59 M |
About Benitec Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Benitec Biopharma Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Benitec Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Benitec Biopharma Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:Check out You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Will Biotechnology sector continue expanding? Could Benitec diversify its offerings? Factors like these will boost the valuation of Benitec Biopharma. Projected growth potential of Benitec fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Benitec Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.07) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Benitec Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Benitec Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Benitec Biopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.